Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biochem Pharma

Executive Summary

$150 mil. profit expected in fiscal year 1999 as the company completes divestiture of its diagnostics program and aggressively expands its anti-infective and oncology pipeline, Biochem Pharma CEO Francesco Bellini, PhD, told analysts Jan. 11. Company earnings for FY 98 are $110 mil., with $800 mil. in lamivudine sales (Epivir and Epivir HBV). The company believes that the September approval of DuPont's Sustiva non-nucleoside analog reverse transcriptase inhibitor will help boost Epivir sales in 1999 as part of an AZT/3TC/Sustiva combination therapy
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel